Genetic Polymorphisms in Long Noncoding RNA H19 Are Associated With Susceptibility to Breast Cancer in Chinese Population.

From the Department of Surgery Medicine, Division of Thoracic Surgery, The First Affiliated Hospital, Zhengzhou University (ZX); Department of Epidemiology and Statistics, College of Public Health, Zhengzhou University (RY, CS, PW, KW); Henan Key Laboratory of Tumor Epidemiology (RY, CS, PW, KW); and Department of Hospital Infection Management, Affiliated Cancer Hospital of Zhengzhou University (FD), Zhengzhou, China.

Abstract

H19, a maternally expressed imprinted gene transcribing a long noncoding RNA, has previously been reported to be involved in tumorigenesis and cancer progression. However, the association between the H19 polymorphisms and breast cancer (BC) susceptibility has remained elusive. The aim of this study was to evaluate the associations between 2 H19 haplotype tagging SNPs (rs3741219 T>C, rs217727 C>T) and the risk of breast cancer. Our study comprised 464 BC patients and 467 cancer-free controls in China. rs3741219 and rs217727 were genotyped with polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) and created restriction site PCR (CRS-RFLP) assays, respectively. False-positive report probability (FPRP) was calculated to test the false-positive association. On performing univariate analysis, no significant association between H19 polymorphisms (rs3741219 and rs217727) and BC was observed. However, in further stratified analyses, CT+TT genotypes of rs217727 had a significantly lower risk of breast cancer among women with number of pregnancy >2 (OR = 0.79; 95% CI = 0.55-0.97). CT genotype of rs217727 was associated with ER positivity (OR = 2.19; 95 % CI = 1.07-4.45) and HER-2 positivity (OR = 1.34; 95 % CI = 1.05-2.12). It was proved that our results were less likely to be false positives according to false-positive report probability calculation. Our findings extend available data on the association of H19 polymorphisms and BC susceptibility. Further validation in large population or cohort studies is needed.